Bristol-Myers Squibb Company (BMY)
|Net Income (ttm)||6.25B|
|Ex-Dividend Date||Jun 30, 2022|
|Day's Range||77.99 - 79.17|
|52-Week Range||53.22 - 80.59|
|Price Target||82.23 (+5.0%)|
|Earnings Date||Jul 27, 2022|
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients w... [Read more...]
Financial PerformanceFinancial Statements
According to 28 analysts, the average rating for BMY stock is "Buy." The 12-month stock price forecast is 82.23, which is an increase of 5.04% from the latest price.
Healthcare is the one sector that has everything an investor needs to navigate the market uncertainty, says Virtus Investment Partners' Joe Terranova. “XLV” is down nearly 10% year-to-date.
All-time highs for pharma stocks: Names to trade now
Big pharma surges, and here are the names to trade. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Dan Nathan, Courtney Garcia and Karen Finerman.
Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.
Final Trades: CHPT, BMY, WMT & XBI
The final trades of the week. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Steve Grasso, Guy Adami and Pete Najarian.
U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphom...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--U.S. FDA Approves BMS's CAR T Cell Therapy Breyanzi for Use After One Prior Therapy for Relapsed or Refractory Large B-cell Lymphoma
A U.S. judge on Friday refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co of delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, which...
Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preservi...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE:BMY) today announced new post-hoc analyses from the Zeposia (ozanimod) Phase 3 DAYBREAK open-label extension (OLE) and Phase 3 ...
New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Tre...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE:BMY) today announced new data on COVID-19 vaccine responses in participants treated with Zeposia (ozanimod) from the ongoing Ph...
These stocks offer dividend yields ranging from 2% to an astronomical 7.1%.
The EMA validates Bristol Myers' (BMY) type II variation application for the label expansion of Breyanzi for treating relapsed/refractory large B-cell lymphoma after first-line therapy.
European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi in Relapsed or...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Bcell--European Medicines Agency Validates BMS's Application for CAR T Cell Therapy Breyanzi....
One of Berkshire Hathaway's longest-held stocks was given the heave-ho in the first quarter.
NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-four cents ($0.54) per share on the $.10 ...
NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Deepak L. Bhatt, M.D., MPH., to the Board, effective June 14, 2022. Dr. ...
Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.
NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE:BMY) will announce results for the second quarter of 2022 on Wednesday, July 27, 2022. Company executives will review financial result...
NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Goldman Sachs' 43rd Annual Global Healthcare Conference in...
Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.
Dr. Scott Gottlieb on promising new cancer drug data: 'The future is here'
Dr. Scott Gottlieb, former FDA commissioner and CNBC contributor, joins CNBC's 'Squawk Box' to discuss the top drug trial data coming out of the American Society of Clinical Oncology conference in Chicago.